Precision Micro-Dispensing and 3D printing manufacturer, nScrypt, based in Orlando, FL, appointed Dr. Stuart Williams as its Chief Life Science Officer. Dr. Williams will lead nScrypt’s Life Science vertical, based on its bioprinter, which won the 2003 R&D 100 award and will be launched to the International Space Station later this year in a joint project with Techshot, Inc.
Dr. Williams received his Ph. D. in Cell Biology from the University of Delaware, followed by postdoctoral training in Pathology at the Yale School of Medicine. He was Director of Research in the Department of Surgery at Jefferson Medical College and later founded the University of Arizona’s Biomedical Engineering Program. He was later the Scientific Director of the Cardiovascular Innovation Institute, a partnership between Jewish Hospital and the University of Louisville in Louisville, Kentucky.
He recently established the Bioficial Organs Program to create human tissues and organs for clinical therapeutics and in vitro drug testing using a patient’s own cells. Central to this effort is the use of 3D bioprinting technologies. He is a Fellow of the American Heart Association and a Fellow of the American Institute of Medical and Biological Engineering.
“The nScrypt BioAssembly Tool, or BAT, is the gold standard of bioprinters. I look forward to working with nScrypt to offer a complete bioprinting solution,” Dr. Williams commented. Dr. Williams will speak for nScrypt on the Bioprinting Panel at the upcoming conference called “Additive Manufacturing Strategies: The Future of 3D Printing in Medicine and Dentistry, which will take place in Boston on January 29-31-2019.
